312 results on '"Daniele, Gennaro"'
Search Results
2. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis
3. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
4. Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.
5. Characterization of shared neoantigens in Endometrial Cancer with Microsatellite Instability
6. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers
7. Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges.
8. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
9. Extension of the SPIRIT 2013 Statement for Factorial Randomized Trials—A Step Toward Transparency and the Curse of Interaction
10. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine
11. Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients
12. Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials
13. The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
14. Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial
15. Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers
16. Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians’ practice
17. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial
18. EGFR Mutations
19. List of Contributors
20. Abstract CT126: An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
21. Data from Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
22. Supplementary Figures S1-S2 from Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
23. Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
24. DNA response and repair gene mutations as a signature for pembrolizumab response in never-smoker non-small lung cancer: real word approach and patient similarity network analysis
25. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
26. Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients
27. Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors
28. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
29. Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center
30. Treatment of small cell lung cancer
31. Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go
32. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis
33. Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
34. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
35. Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
36. Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment
37. Abstract LB040: Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study
38. Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer
39. The role of artificial intelligence in managing multimorbidity and cancer
40. Breast cancer drug approvals issued by EMA: A review of clinical trials
41. Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital
42. FGF Receptor Inhibitors: Role in Cancer Therapy
43. The role of bevacizumab in breast cancer
44. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
45. Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
46. The Role of Artificial Intelligence in Managing Multimorbidity and Cancer
47. Development of a Digital Research Assistant for the Management of Patients’ Enrollment in Oncology Clinical Trials within a Research Hospital
48. Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go
49. Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
50. Immunotherapy in gynecological cancers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.